Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Active Biotech

0.07 SEK

+7.97 %

Less than 1K followers

ACTI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+7.97 %
+1.26 %
-50.89 %
-68.61 %
-24.71 %
-43.11 %
-80.59 %
-83.86 %
-98.43 %

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The project portfolio includes both small, orally active immunomodulatory molecules and antibody-based immunotherapy. The company operates globally. Active Biotech was founded in 1998 and is headquartered in Lund.

Read more
Market cap
171.34M SEK
Turnover
1.21M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/2
2026

Annual report '25

7/5
2026

Interim report Q1'26

20/5
2026

General meeting '26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release11/26/2025, 9:37 AM

Finansinspektionen: Flaggningsmeddelande i Active Biotech AB (publ)

Active Biotech
Press release11/25/2025, 9:00 AM

Active Biotechs patent relaterat till en farmaceutisk formulering av tasquinimod kommer att beviljas i USA

Active Biotech
Press release11/25/2025, 9:00 AM

Active Biotech’s patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Active Biotech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release11/25/2025, 7:30 AM

Idag inleds teckningsperioden i Active Biotechs företrädesemission

Active Biotech
Regulatory press release11/25/2025, 7:30 AM

The subscription period in Active Biotech’s rights issue begins today

Active Biotech
Press release11/24/2025, 8:30 AM

Positiva prekliniska tasquinimod-data i myelofibros publicerade i Blood Advances

Active Biotech
Press release11/24/2025, 8:30 AM

Positive preclinical tasquinimod data in myelofibrosis published in Blood Advances

Active Biotech
Regulatory press release11/21/2025, 9:23 AM

Finansinspektionen: Flaggningsmeddelande i Active Biotech AB (publ)

Active Biotech
Regulatory press release11/20/2025, 2:45 PM

Active Biotech offentliggör informationsdokument avseende företrädesemission

Active Biotech
Regulatory press release11/20/2025, 2:45 PM

Active Biotech publishes information document regarding rights issue

Active Biotech
Regulatory press release11/20/2025, 9:37 AM

Finansinspektionen: Flaggningsmeddelande i Active Biotech AB (publ)

Active Biotech
Regulatory press release11/19/2025, 11:00 AM

Extraordinary General Meeting of Active Biotech AB

Active Biotech
Regulatory press release11/19/2025, 11:00 AM

Extra bolagsstämma i Active Biotech AB

Active Biotech
Regulatory press release11/19/2025, 9:30 AM

Finansinspektionen: Flaggningsmeddelande i Active Biotech AB (publ)

Active Biotech
Regulatory press release11/12/2025, 9:12 AM

Finansinspektionen: Flaggningsmeddelande i Active Biotech AB (publ)

Active Biotech
Press release11/10/2025, 8:45 AM

Redeye: Active Biotech (Q3 Review) - Rights Issue Funds 2026-2027

Active Biotech
Regulatory press release11/6/2025, 7:30 AM

Active Biotech Interim Report Q3 2025

Active Biotech
Regulatory press release11/6/2025, 7:30 AM

Active Biotech delårsrapport Q3 2025

Active Biotech
Press release11/3/2025, 3:30 PM

Prekliniska data för tasquinimod i kombination med T-cellsaktivering kommer att presenteras vid ASH 2025

Active Biotech
Press release11/3/2025, 3:30 PM

Preclinical data of tasquinimod in combination with T cell activation to be presented at ASH 2025

Active Biotech
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.